| Symbol | MGNX |
|---|---|
| Name | MACROGENICS INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 9704 MEDICAL CENTER DRIVE, Rockville, MD 20850 |
| Telephone | 301-251-5172 |
| Fax | — |
| — | |
| Website | https://www.macrogenics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001125345 |
| Description | Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. The companys strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The companys intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them. Additional info from NASDAQ: |
2026-05-20 20:14
Director O'Brien Federica F. 🟡 adjusted position in 25.8K shares (3 derivative) of MACROGENICS INC (MGNX) at $4.52 Transaction Date: May 18, 2026 | Filing ID: 000002
Read more
2026-05-20 20:14
Director Jackson Scott Thomas 🟡 adjusted position in 25.8K shares (3 derivative) of MACROGENICS INC (MGNX) at $4.52 Transaction Date: May 18, 2026 | Filing ID: 000002
Read more
2026-05-20 20:14
Director HEIDEN WILLIAM K 🟡 adjusted position in 25.8K shares (3 derivative) of MACROGENICS INC (MGNX) at $4.52 Transaction Date: May 18, 2026 | Filing ID: 000002
Read more
2026-05-20 20:13
Director SIEGEL JAY PHILIP 🟡 adjusted position in 0 shares (1 derivative) of MACROGENICS INC (MGNX) Transaction Date: May 18, 2026 | Filing ID: 000002
Read more
2026-05-20 20:13
Director Liu Margaret 🟡 adjusted position in 25.8K shares (3 derivative) of MACROGENICS INC (MGNX) at $4.52 Transaction Date: May 18, 2026 | Filing ID: 000002
Read more
2026-05-20 20:13
Director Chhabra Meenu 🟡 adjusted position in 25.8K shares (3 derivative) of MACROGENICS INC (MGNX) at $4.52 Transaction Date: May 18, 2026 | Filing ID: 000003
Read more
2026-05-20 20:13
Director HURWITZ EDWARD 🟡 adjusted position in 25.8K shares (3 derivative) of MACROGENICS INC (MGNX) at $4.52 Transaction Date: May 18, 2026 | Filing ID: 000002
Read more
2026-05-20 20:13
Director STUMP DAVID C 🟡 adjusted position in 25.8K shares (3 derivative) of MACROGENICS INC (MGNX) at $4.52 Transaction Date: May 18, 2026 | Filing ID: 000002
Read more
2026-05-20 20:13
Director Ferrante Karen Jean 🟡 adjusted position in 25.8K shares (3 derivative) of MACROGENICS INC (MGNX) at $4.52 Transaction Date: May 18, 2026 | Filing ID: 000002
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT01206504 | Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Di… | — | West Nile Virus Infection | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT04678466 | Flotetuzumab Expanded Access Program | — | Acute Myeloid Leukemia | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT07071961 | Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-ri… | Phase2 | Colorectal Cancer | Suspended | 2026-02-11 | 2029-05-01 | ClinicalTrials.gov |
| NCT07223567 | A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or … | Phase2 | Rectal Cancer | Withdrawn | 2025-10-27 | 2026-01-22 | ClinicalTrials.gov |
| NCT06730347 | A Study of Lorigerlimab in Participants With Advanced Solid Tumors | Phase2 | Platinum-resistant Ovarian Cancer | Recruiting | 2025-05-01 | 2027-08-01 | ClinicalTrials.gov |
| NCT06723236 | A Study of MGC028 in Participants With Advanced Solid Tumors | Phase1 | Advanced Solid Tumors | Recruiting | 2025-02-13 | 2027-04-01 | ClinicalTrials.gov |
| NCT06227546 | MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung … | Phase2 | Extensive-stage Small-cell Lung Cancer | Active_Not_Recruiting | 2024-04-15 | 2026-05-01 | ClinicalTrials.gov |
| NCT06242470 | A Study of MGC026 in Participants With Advanced Solid Tumors | Phase1 | Advanced Solid Tumor | Recruiting | 2024-03-06 | 2028-10-01 | ClinicalTrials.gov |
| NCT06014255 | Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prost… | Phase2 | Prostate Cancer | Recruiting | 2024-02-16 | 2029-03-01 | ClinicalTrials.gov |
| NCT05848011 | A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With … | Phase2 | Androgen-Independent Prostatic Cancer | Completed | 2023-09-28 | 2026-03-16 | ClinicalTrials.gov |
| NCT05551117 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration… | Phase2 | Castration-Resistant Prostatic Cancer | Terminated | 2023-06-13 | 2025-01-23 | ClinicalTrials.gov |
| NCT05475171 | Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION) | Phase2 | Metastatic Cancer | Recruiting | 2022-12-13 | 2026-06-30 | ClinicalTrials.gov |
| NCT05506956 | Post-transplant Flotetuzumab for AML | Phase1 | Leukemia, Myeloid, Acute | Completed | 2022-10-20 | 2024-06-18 | ClinicalTrials.gov |
| NCT05261191 | A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antire… | Phase1 | Human Immunodeficiency Virus I Infection | Completed | 2022-09-26 | 2024-05-29 | ClinicalTrials.gov |
| NCT05362773 | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignanc… | Phase1 | Leukemia, Acute Myeloid | Recruiting | 2022-07-13 | 2027-05-01 | ClinicalTrials.gov |
| NCT05227131 | Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast… | Phase2 | Metastatic Breast Cancer | Withdrawn | 2022-05-15 | 2024-10-01 | ClinicalTrials.gov |
| NCT05293496 | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Soli… | Phase1 | Advanced Solid Tumor | Completed | 2022-04-19 | 2025-08-26 | ClinicalTrials.gov |
| NCT04582864 | Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Synd… | Phase2 | Relapsed Acute Myeloid Leukemia | Terminated | 2021-05-20 | 2024-07-26 | ClinicalTrials.gov |
| NCT04634825 | Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer | Phase2 | Head and Neck Cancer | Terminated | 2021-03-17 | 2022-07-29 | ClinicalTrials.gov |
| NCT04622774 | First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors | Phase1 | Advanced Solid Tumor | Completed | 2020-10-29 | 2023-12-28 | ClinicalTrials.gov |
| NCT04425018 | MARGetuximab Or Trastuzumab (MARGOT) | Phase2 | Breast Cancer | Active_Not_Recruiting | 2020-07-13 | 2027-07-01 | ClinicalTrials.gov |
| NCT04129320 | Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and … | Phase2 | Head and Neck Cancer | Withdrawn | 2019-10-01 | 2022-10-01 | ClinicalTrials.gov |
| NCT04082364 | Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3… | Phase2 | Gastric Cancer | Completed | 2019-09-30 | 2025-03-25 | ClinicalTrials.gov |
| NCT03761017 | MGD019 DART® Protein in Unresectable/Metastatic Cancer | Phase1 | Squamous Cell Non Small Cell Lung Cancer | Completed | 2018-12-12 | 2025-01-27 | ClinicalTrials.gov |
| NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | Phase1 | Squamous Cell Carcinoma of Head and Neck | Terminated | 2018-11-21 | 2023-03-18 | ClinicalTrials.gov |
| NCT03570918 | MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy | Phase1 | HIV-1-infection | Completed | 2018-09-25 | 2021-09-28 | ClinicalTrials.gov |
| NCT03531632 | MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer | Phase1 | Colorectal Cancer Metastatic | Completed | 2018-06-04 | 2020-02-08 | ClinicalTrials.gov |
| NCT03406949 | MGD009/MGA012 Combination in Relapsed/Refractory Cancer | Phase1 | Advanced Solid Tumors | Completed | 2018-02-27 | 2022-04-27 | ClinicalTrials.gov |
| NCT03219268 | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms | Phase1 | Advanced Solid Tumors | Completed | 2017-08-18 | 2023-02-08 | ClinicalTrials.gov |
| NCT02923180 | Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-… | Phase2 | Prostate Cancer | Active_Not_Recruiting | 2017-02-14 | 2026-07-01 | ClinicalTrials.gov |
| NCT02982941 | Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors | Phase1 | Neuroblastoma | Completed | 2016-12-01 | 2019-05-22 | ClinicalTrials.gov |
| NCT02689284 | Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gas… | Phase1 | Gastric Cancer | Completed | 2016-01-01 | 2021-01-01 | ClinicalTrials.gov |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | Phase1 | Mesothelioma | Terminated | 2015-09-01 | 2019-11-25 | ClinicalTrials.gov |
| NCT02492711 | Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatmen… | Phase3 | HER-2 Positive Breast Cancer | Completed | 2015-08-24 | 2022-06-14 | ClinicalTrials.gov |
| NCT02475213 | Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA… | Phase1 | Melanoma | Completed | 2015-07-01 | 2021-08-18 | ClinicalTrials.gov |
| NCT02381314 | Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refrac… | Phase1 | Melanoma | Completed | 2015-03-26 | 2018-09-26 | ClinicalTrials.gov |
| NCT02376036 | Phase 1 Study of MGD010 in Healthy Subjects | Phase1 | Healthy Subjects | Completed | 2015-02-01 | 2017-02-01 | ClinicalTrials.gov |
| NCT02248805 | Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma | Phase1 | Colorectal Carcinoma | Completed | 2014-10-01 | 2018-07-02 | ClinicalTrials.gov |
| NCT02152956 | Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Mye… | Phase1 | AML | Terminated | 2014-06-09 | 2022-07-05 | ClinicalTrials.gov |
| NCT01918930 | Tissue Procurement Substudy for Participants in Study CP-MGA271-01 | Phase1 | Melanoma | Terminated | 2013-07-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT01828021 | Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With… | Phase2 | Breast Cancer | Completed | 2013-03-01 | 2017-04-14 | ClinicalTrials.gov |
| NCT01391143 | Safety Study of MGA271 in Refractory Cancer | Phase1 | Prostate Cancer | Completed | 2011-07-01 | 2019-04-18 | ClinicalTrials.gov |
| NCT01189422 | Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes | Phase1 | Type 1 Diabetes Mellitus | Terminated | 2010-08-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT01148849 | Safety Study of MGAH22 in HER2-positive Carcinomas | Phase1 | Breast Cancer | Completed | 2010-07-01 | 2022-06-14 | ClinicalTrials.gov |
| NCT00954915 | Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Mo… | Phase1 | Psoriasis | Terminated | 2009-12-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00920582 | Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adu… | Phase3 | Type 1 Diabetes Mellitus | Terminated | 2009-09-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT00927953 | Treatment of West Nile Virus With MGAWN1 | Phase2 | West Nile Neuroinvasive Disease | Terminated | 2009-05-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT00870818 | Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed … | Na | Type 1 Diabetes Mellitus | Terminated | 2009-02-01 | 2011-05-01 | ClinicalTrials.gov |
| NCT00625586 | Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic … | Phase2 | Pancreatic Cancer | Terminated | 2008-04-15 | 2009-03-18 | ClinicalTrials.gov |
| NCT00515385 | A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in He… | Phase1 | West Nile Virus | Completed | 2007-08-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00385697 | The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent… | Phase2 | Type 1 Diabetes Mellitus | Completed | 2006-10-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT00101972 | RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma | Phase1 | Cancer | Completed | 2004-12-01 | 2008-05-01 | ClinicalTrials.gov |
Total clinical trials: 52
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| MGD013 | Other | Phase PHASE2 | Head and Neck Cancer | WITHDRAWN | NCT04129320 |
| MGA012 | Other | Phase PHASE2 | Head and Neck Cancer | WITHDRAWN | NCT04129320 |
| enoblituzumab | Other | Phase PHASE2 | Head and Neck Cancer | WITHDRAWN | NCT04129320 |
| MGD013 | Other | Phase PHASE2 | Head and Neck Cancer | WITHDRAWN | NCT04129320 |
| MGA012 | Other | Phase PHASE2 | Head and Neck Cancer | WITHDRAWN | NCT04129320 |
| enoblituzumab | Other | Phase PHASE2 | Head and Neck Cancer | WITHDRAWN | NCT04129320 |
| MGD007 + MGA012 | Other | Phase PHASE1 | Colorectal Cancer Metastatic | COMPLETED | NCT03531632 |
| Enoblituzumab | Other | Phase PHASE1 | Neuroblastoma | COMPLETED | NCT02982941 |
| Enoblituzumab | Other | Phase PHASE1 | Neuroblastoma | COMPLETED | NCT02982941 |
| MGD009 | Other | Phase PHASE1 | Mesothelioma | TERMINATED | NCT02628535 |
| MGD009 | Other | Phase PHASE1 | Mesothelioma | TERMINATED | NCT02628535 |
| MGD009 | Other | Phase PHASE1 | Mesothelioma | TERMINATED | NCT02628535 |
| enoblituzumab plus ipilimumab | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02381314 |
| enoblituzumab plus ipilimumab | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02381314 |
| Hepatitis A vaccine | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT02376036 |
| Placebo | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT02376036 |
| MGD010 | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT02376036 |
| Hepatitis A vaccine | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT02376036 |
| Placebo | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT02376036 |
| MGD010 | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT02376036 |
| MGD007 | Other | Phase PHASE1 | Colorectal Carcinoma | COMPLETED | NCT02248805 |
| MGD007 | Other | Phase PHASE1 | Colorectal Carcinoma | COMPLETED | NCT02248805 |
| MGA271 | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT01918930 |
| MGA271 | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT01918930 |
| MGA271 | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01391143 |
| MGA271 | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT01391143 |
| Placebo - normal saline | Other | Phase PHASE2 | West Nile Neuroinvasive Disease | TERMINATED | NCT00927953 |
| MGAWN1 | Other | Phase PHASE2 | West Nile Neuroinvasive Disease | TERMINATED | NCT00927953 |
| Placebo - normal saline | Other | Phase PHASE2 | West Nile Neuroinvasive Disease | TERMINATED | NCT00927953 |
| MGAWN1 | Other | Phase PHASE2 | West Nile Neuroinvasive Disease | TERMINATED | NCT00927953 |
| MGAWN1 | Other | Preclinical | West Nile Virus Infection | NO_LONGER_AVAILABLE | NCT01206504 |
| MGAWN1 | Other | Preclinical | West Nile Virus Infection | NO_LONGER_AVAILABLE | NCT01206504 |
| MGAWN1 | Other | Preclinical | West Nile Virus Infection | NO_LONGER_AVAILABLE | NCT01206504 |
| Placebo | Other | Phase PHASE1 | West Nile Virus | COMPLETED | NCT00515385 |
| MGAWN1 | Other | Phase PHASE1 | West Nile Virus | COMPLETED | NCT00515385 |
| Placebo | Other | Phase PHASE1 | West Nile Virus | COMPLETED | NCT00515385 |
| MGAWN1 | Other | Phase PHASE1 | West Nile Virus | COMPLETED | NCT00515385 |
| monoclonal antibody RAV12 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00101972 |
| retifanlimab | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT03406949 |
| obrindatamab | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT03406949 |
| flotetuzumab | Other | Preclinical | Acute Myeloid Leukemia | NO_LONGER_AVAILABLE | NCT04678466 |
| flotetuzumab | Other | Preclinical | Acute Myeloid Leukemia | NO_LONGER_AVAILABLE | NCT04678466 |
| Capecitabine | Other | Phase PHASE2 | Metastatic Breast Cancer | WITHDRAWN | NCT05227131 |
| Tucatinib | Other | Phase PHASE2 | Metastatic Breast Cancer | WITHDRAWN | NCT05227131 |
| Margetuximab | Other | Phase PHASE2 | Metastatic Breast Cancer | WITHDRAWN | NCT05227131 |
| MGD014 | Other | Phase PHASE1 | HIV-1-infection | COMPLETED | NCT03570918 |
| Gemcitabine | Other | Phase PHASE2 | Pancreatic Cancer | TERMINATED | NCT00625586 |
| RAV12 | Other | Phase PHASE2 | Pancreatic Cancer | TERMINATED | NCT00625586 |
| Gemcitabine | Other | Phase PHASE2 | Pancreatic Cancer | TERMINATED | NCT00625586 |
| RAV12 | Other | Phase PHASE2 | Pancreatic Cancer | TERMINATED | NCT00625586 |
| Tebotelimab | Other | Phase PHASE2 | Head and Neck Cancer | TERMINATED | NCT04634825 |
| Retifanlimab | Other | Phase PHASE2 | Head and Neck Cancer | TERMINATED | NCT04634825 |
| Enoblituzumab | Other | Phase PHASE2 | Head and Neck Cancer | TERMINATED | NCT04634825 |
| Tebotelimab | Other | Phase PHASE2 | Head and Neck Cancer | TERMINATED | NCT04634825 |
| Retifanlimab | Other | Phase PHASE2 | Head and Neck Cancer | TERMINATED | NCT04634825 |
| Enoblituzumab | Other | Phase PHASE2 | Head and Neck Cancer | TERMINATED | NCT04634825 |
| margetuximab | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT03219268 |
| tebotelimab 1200 mg | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT03219268 |
| tebotelimab 800 mg | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT03219268 |
| tebotelimab 600 mg | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT03219268 |
| tebotelimab 400 mg | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT03219268 |
| tebotelimab 300 mg | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT03219268 |
| tebotelimab 120 mg | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT03219268 |
| tebotelimab 30 mg | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT03219268 |
| tebotelimab 10 mg | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT03219268 |
| tebotelimab 3 mg | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT03219268 |
| tebotelimab 1 mg | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT03219268 |
| Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose | Other | Phase PHASE1 | AML | TERMINATED | NCT02152956 |
| Ruxolitinib | Other | Phase PHASE1 | AML | TERMINATED | NCT02152956 |
| Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose | Other | Phase PHASE1 | AML | TERMINATED | NCT02152956 |
| Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose | Other | Phase PHASE1 | AML | TERMINATED | NCT02152956 |
| Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose | Other | Phase PHASE1 | AML | TERMINATED | NCT02152956 |
| Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose | Other | Phase PHASE1 | AML | TERMINATED | NCT02152956 |
| Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose | Other | Phase PHASE1 | AML | TERMINATED | NCT02152956 |
| Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off | Other | Phase PHASE1 | AML | TERMINATED | NCT02152956 |
| Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off | Other | Phase PHASE1 | AML | TERMINATED | NCT02152956 |
| Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off | Other | Phase PHASE1 | AML | TERMINATED | NCT02152956 |
| Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off | Other | Phase PHASE1 | AML | TERMINATED | NCT02152956 |
| Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose | Other | Phase PHASE1 | AML | TERMINATED | NCT02152956 |
| Ruxolitinib | Other | Phase PHASE1 | AML | TERMINATED | NCT02152956 |
| Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose | Other | Phase PHASE1 | AML | TERMINATED | NCT02152956 |
| Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose | Other | Phase PHASE1 | AML | TERMINATED | NCT02152956 |
| Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose | Other | Phase PHASE1 | AML | TERMINATED | NCT02152956 |
| Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose | Other | Phase PHASE1 | AML | TERMINATED | NCT02152956 |
| Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose | Other | Phase PHASE1 | AML | TERMINATED | NCT02152956 |
| Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off | Other | Phase PHASE1 | AML | TERMINATED | NCT02152956 |
| Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off | Other | Phase PHASE1 | AML | TERMINATED | NCT02152956 |
| Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off | Other | Phase PHASE1 | AML | TERMINATED | NCT02152956 |
| Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off | Other | Phase PHASE1 | AML | TERMINATED | NCT02152956 |
| lorigerlimab | Other | Phase PHASE1 | Advanced Solid Tumor | COMPLETED | NCT05293496 |
| vobramitamab duocarmazine | Other | Phase PHASE1 | Advanced Solid Tumor | COMPLETED | NCT05293496 |
| lorigerlimab | Other | Phase PHASE1 | Advanced Solid Tumor | COMPLETED | NCT05293496 |
| vobramitamab duocarmazine | Other | Phase PHASE1 | Advanced Solid Tumor | COMPLETED | NCT05293496 |
| Donor lymphocyte infusion | Other | Phase PHASE2 | Relapsed Acute Myeloid Leukemia | TERMINATED | NCT04582864 |
| Flotetuzumab | Other | Phase PHASE2 | Relapsed Acute Myeloid Leukemia | TERMINATED | NCT04582864 |
| IMGC936 | Other | Phase PHASE1 | Advanced Solid Tumor | COMPLETED | NCT04622774 |
| IMGC936 | Other | Phase PHASE1 | Advanced Solid Tumor | COMPLETED | NCT04622774 |
| margetuximab | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT01148849 |
| Lorigerlimab | Other | Phase PHASE1 | Squamous Cell Non Small Cell Lung Cancer | COMPLETED | NCT03761017 |
| Lorigerlimab | Other | Phase PHASE1 | Squamous Cell Non Small Cell Lung Cancer | COMPLETED | NCT03761017 |
| Margetuximab | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01828021 |
| Pembrolizumab | Other | Phase PHASE1 | Gastric Cancer | COMPLETED | NCT02689284 |
| Margetuximab 15 mg | Other | Phase PHASE1 | Gastric Cancer | COMPLETED | NCT02689284 |
| Margetuximab 10 mg/kg | Other | Phase PHASE1 | Gastric Cancer | COMPLETED | NCT02689284 |
| Physician's choice of chemotherapy. | Drug | Phase PHASE3 | HER-2 Positive Breast Cancer | COMPLETED | NCT02492711 |
| Trastuzumab | Other | Phase PHASE3 | HER-2 Positive Breast Cancer | COMPLETED | NCT02492711 |
| Margetuximab | Other | Phase PHASE3 | HER-2 Positive Breast Cancer | COMPLETED | NCT02492711 |
| MGD014 | Other | Phase PHASE1 | Human Immunodeficiency Virus I Infection | COMPLETED | NCT05261191 |
| MGD020 | Other | Phase PHASE1 | Human Immunodeficiency Virus I Infection | COMPLETED | NCT05261191 |
| MGD014 | Other | Phase PHASE1 | Human Immunodeficiency Virus I Infection | COMPLETED | NCT05261191 |
| MGD020 | Other | Phase PHASE1 | Human Immunodeficiency Virus I Infection | COMPLETED | NCT05261191 |
| MGC018 | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06227546 |
| Enoblituzumab | Other | Phase PHASE2 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT02923180 |
| Enoblituzumab | Other | Phase PHASE2 | Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT02923180 |
| vobramitamab duocarmazine | Other | Phase PHASE1 | Squamous Cell Carcinoma of Head and Neck | TERMINATED | NCT03729596 |
| vobramitamab duocarmazine | Other | Phase PHASE1 | Squamous Cell Carcinoma of Head and Neck | TERMINATED | NCT03729596 |
| retifanlimab | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02475213 |
| Enoblituzumab Schedule 2 | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02475213 |
| Pembrolizumab | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02475213 |
| Enoblituzumab Schedule 1 | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02475213 |
| retifanlimab | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02475213 |
| Enoblituzumab Schedule 2 | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02475213 |
| Pembrolizumab | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02475213 |
| Enoblituzumab Schedule 1 | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02475213 |
| Flotetuzumab | Other | Phase PHASE1 | Leukemia, Myeloid, Acute | COMPLETED | NCT05506956 |
| MGC028 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT06723236 |
| Standard of Care | Other | Phase PHASE2 | Prostate Cancer | RECRUITING | NCT06014255 |
| Enoblituzumab | Other | Phase PHASE2 | Prostate Cancer | RECRUITING | NCT06014255 |
| Trastuzumab | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04425018 |
| Margetuximab | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04425018 |
| Pertuzumab | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04425018 |
| Paclitaxel | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04425018 |
| Trastuzumab | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04425018 |
| Margetuximab | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04425018 |
| Pertuzumab | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04425018 |
| Paclitaxel | Other | Phase PHASE2 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04425018 |
| Lorigerlimab | Other | Phase PHASE2 | Metastatic Cancer | RECRUITING | NCT05475171 |
| MGD024 | Other | Phase PHASE1 | Leukemia, Acute Myeloid | RECRUITING | NCT05362773 |
| MGD024 | Other | Phase PHASE1 | Leukemia, Acute Myeloid | RECRUITING | NCT05362773 |
| MGC026 Dose for Expansion | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06242470 |
| MGC026 Dose Escalation | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06242470 |
| MGC026 Dose for Expansion | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06242470 |
| MGC026 Dose Escalation | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06242470 |
| MGC026 Dose for Expansion | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06242470 |
| MGC026 Dose Escalation | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06242470 |
| Enzalutamide | Other | Phase PHASE2 | Castration-Resistant Prostatic Cancer | TERMINATED | NCT05551117 |
| Abiraterone | Other | Phase PHASE2 | Castration-Resistant Prostatic Cancer | TERMINATED | NCT05551117 |
| vobramitamab duocarmazine | Other | Phase PHASE2 | Castration-Resistant Prostatic Cancer | TERMINATED | NCT05551117 |
| vobramitamab duocarmazine 2.7 mg (Arm B) | Other | Phase PHASE2 | Castration-Resistant Prostatic Cancer | TERMINATED | NCT05551117 |
| vobramitamab duocarmazine 2.0 mg (Arm A) | Other | Phase PHASE2 | Castration-Resistant Prostatic Cancer | TERMINATED | NCT05551117 |
| Lorigerlimab | Other | Phase PHASE2 | Platinum-resistant Ovarian Cancer | RECRUITING | NCT06730347 |
| Lorigerlimab | Other | Phase PHASE2 | Platinum-resistant Ovarian Cancer | RECRUITING | NCT06730347 |
| Lorigerlimab | Other | Phase PHASE2 | Platinum-resistant Ovarian Cancer | RECRUITING | NCT06730347 |
| Prednisone | Other | Phase PHASE2 | Androgen-Independent Prostatic Cancer | ACTIVE_NOT_RECRUITING | NCT05848011 |
| docetaxel | Other | Phase PHASE2 | Androgen-Independent Prostatic Cancer | ACTIVE_NOT_RECRUITING | NCT05848011 |
| lorigerlimab | Other | Phase PHASE2 | Androgen-Independent Prostatic Cancer | ACTIVE_NOT_RECRUITING | NCT05848011 |
| MGC018 | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06227546 |
| MGC018 | Other | Phase PHASE2 | Extensive-stage Small-cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT06227546 |
| Prednisone | Other | Phase PHASE2 | Androgen-Independent Prostatic Cancer | COMPLETED | NCT05848011 |
| docetaxel | Other | Phase PHASE2 | Androgen-Independent Prostatic Cancer | COMPLETED | NCT05848011 |
| lorigerlimab | Other | Phase PHASE2 | Androgen-Independent Prostatic Cancer | COMPLETED | NCT05848011 |
Total products: 161